Managing people with opioid-use disorder in the emergency departmentCanadian Association of Emergency Physicians offers recommendations for emergency healthcare providers to help address Canada’s opioid crisis. U.S. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or laterU.S. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later NSAIDs may cause rare kidney problems in unborn babies and/or low levels of amniotic fluid. 5 Tips: Managing lower back pain Guidelines recommend pharmacists provide take-home naloxone to all opioid users Take-home naloxone kits are publicly funded in all Canadian provinces and territories and have been shown to effectively reduce opioid-related deaths. Emgality (galcanezumab) now indicated to reduce cluster headache frequency CGRP binding antibody is first drug approved by Health Canada to help prevent episodic cluster headaches New Canadian consensus guidelines for pharmacist prescribing of naloxone All patients receiving an opioid should be provided with take-home naloxone and counselled by a pharmacist Be alert for potential drug interactions with medical and recreational cannabis Review provides a comprehensive list of drug-drug interactions, with particular focus on Rx drugs with a narrow therapeutic index Acetaminophen–ibuprofen fixed-dose combo product coming soon to Canada Indicated in adults for short-term management of mild to moderate acute pain and for reduction of fever Sponsored Q&A: Polysporin topical antibiotics for relief of minor injuries Medical cannabis and the unmet needs of chronic pain in Canada First Previous 9 10 11 12 13 Next Last